What it sells
Predicts drug toxicity in human tissue before clinical trials
Business model breakdown
Buyer: who owns the budget?
UnverifiedDrug-discovery R&D/biology leads at pharma and biotech.
Trigger: what makes them buy now?
UnverifiedAI generates therapeutic hypotheses faster than animals, organoids and trials can validate them; animal and clinical testing are costly and weak proxies.
Workflow: what inputs become what output?
Manufacture parallel arrays of human tissue, perturb and observe them, train models to simulate them, and use closed-loop results to verify AI-generated biological predictions.
Distribution: how it reaches customers
Contact form only; no self-serve.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-09 | — | $20M | — | alleywatch.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.